Join the Crohn's Disease group to help and get support from people like you.
Crohn's Disease News (Page 2)
Related terms: Crohns
Crohn's, Colitis Vary by Race, Gender
FRIDAY, Jan. 5, 2023 – Crohn's disease and ulcerative colitis show different patterns of incidence by race, gender and even place of birth, a new U.S. study finds. The two illnesses are each...
Guidelines Developed for Crohn Disease Management With Biomarkers
FRIDAY, Dec. 15, 2023 – For patients with Crohn disease (CD), biomarkers can inform disease management in symptomatic and asymptomatic disease, according to a clinical practice guideline issued by...
Changes in Biochemical, Hematological Parameters Seen Before IBD Diagnosis
MONDAY, Dec. 11, 2023 – Changes in multiple biochemical and hematological parameters occur up to eight years before diagnosis of Crohn disease and up to three years before diagnosis of ulcerative...
Histologic Inflammation With IBD Tied to Serious Infections
FRIDAY, Dec. 8, 2023 – Histologic inflammation with inflammatory bowel disease (IBD) is an independent risk factor for serious infections, according to a study published online Oct. 29 in Clinical ...
Higher Visceral Adipose Tissue May Need Higher Infliximab Levels for IBD Remission
WEDNESDAY, Nov. 15, 2023 – Patients with inflammatory bowel disease (IBD) and high visceral adipose tissue (VAT) may have more difficulty achieving higher infliximab levels necessary to achieve...
Subtle Changes Could Predict Inflammatory Bowel Disease Years Before Symptoms Hit
MONDAY, Nov. 13, 2023 (Healthday News) – Inflammatory bowel disease starts to develop years before patients come down with symptoms, a new study suggests. Gut changes can be detected in blood tests...
Inflammatory Bowel Disease Increases Risk for Later Arrhythmias
MONDAY, Nov. 6, 2023 – Patients with inflammatory bowel disease (IBD) overall, as well as Crohn disease (CD) and ulcerative colitis (UC) individually, have an increased risk for developing later...
FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
October 31, 2023 – Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory...
Monthly News Roundup - October 2023
FDA Clears Loqtorzi as First Treatment for Nasopharyngeal Carcinoma (NPC) In October, the U.S. Food and Drug Administration (FDA) approved Coherus BioSciences’ Loqtorzi (toripalimab-tpzi) to treat a...
FDA Approves Zymfentra (infliximab-dyyb) Subcutaneous Formulation for the Treatment of People With Inflammatory Bowel Disease
JERSEY CITY, N.J.--(BUSINESS WIRE) October 23, 2023 --Today, Celltrion USA announced that the U.S. Food and Drug Administration (FDA) has approved Zymfentra (infliximab-dyyb) for maintenance therapy...
ACG: Prophylactic Low-Dose Aspirin in Pregnancy Does Not Increase IBD Activity
THURSDAY, Oct. 26, 2023 – Use of low-dose aspirin (LDA) among pregnant women with inflammatory bowel disease (IBD) is not associated with an increased risk for disease activity, according to a study...
ACG: Intestinal Ultrasound Monitoring Cuts Time to Treatment Change in IBD
WEDNESDAY, Oct. 25, 2023 – For patients with inflammatory bowel disease (IBD), monitoring by intestinal ultrasound (IUS) results in reduced time to treatment change and to remission, according to a...
COVID Might Raise Odds for Immune Disorders Like Crohn's, Alopecia
TUESDAY, Oct. 10, 2023 – In rare cases, some patients may develop an autoimmune disease following a bout of COVID, Korean researchers report. Conditions such as alopecia (hair loss), psoriasis,...
Autoimmune, Autoinflammatory Connective Tissue Disorders Increased After COVID-19
TUESDAY, Oct. 10, 2023 – COVID-19 is associated with an increased risk for autoimmune and autoinflammatory connective tissue disorders, according to a study published online Oct. 6 in JAMA Network...
FDA Grants Interchangeable Designation to Pfizer’s Biosimilar Abrilada
NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Hum...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Crohn's Disease - Maintenance, Inflammatory Bowel Disease
Related drug support groups
Humira, Remicade, Entyvio, Stelara, Skyrizi, cholestyramine, adalimumab, budesonide